THE BUDGET IMPACT OF USING FIDAXOMICIN FOR HOSPITALISED CDI PATIENTS FROM THE DANISH HEALTH CARE PERSPECTIVE

Author(s)

Nordling S, Cockburn E
Astellas Pharma a/s, Kastrup, Denmark

OBJECTIVES: Analyse the budget impact in Region Hovedstaden in Denmark (Region H), if all Clostridium difficile (CDI) hospitalised patients received fidaxomicin instead of vancomycin during one year.  METHODS:  The Danish national patient database provided the number of hospitalised patients and length of stay (LOS) for CDI patients (ICD-10: A047). A phase III trial provided the risk of a first and second CDI recurrence [Cornelly 2012]. Cost per hospital stay calculated by LOS multiplied by cost per bed day (DKK 6,000) plus drug costs, vancomycin (DKK 300), fidaxomicin (DKK 11,641).  RESULTS: In Region H 840 CDI patients were hospitalised in 2012. Assuming the same outcome as the trial, the total number of CDI hospitalisations would decrease from 1,104 with vancomycin ((23,2% risk of 1st recurrence (23.2% *840 = 195); 35.5% risk of 2nd recurrence (35.5%*195 = 69)) to 930 with fidaxomicin ((9.0% risk of 1st recurrence (9.0%*840=76); 19.7% risk of 2nd recurrence (19.7% *76= 15)). Fidaxomicin prevents 174 hospitalisations compared to vancomycin. Assuming CDI is the primary diagnosis, with an average LOS of 9.0 days, the healthcare cost will increase by 2% with fidaxomicin. Assuming CDI is the secondary diagnosis, with an average LOS of 16.8 days, the healthcare cost will decrease by 6% with fidaxomicin. Assuming the average LOS for CDI patients is 13.3 days, the healthcare cost will decrease with 4%, and assuming LOS is 10 days, using fidaxomicin is cost neutral. CONCLUSIONS: In Region H, if all hospitalised CDI patients received fidaxomicin the number of recurrences decreases by 66% and the total number of cases decreases by 16%, compared to vancomycin usage. From the healthcare payer perspective fidaxomicin reduces recurrences, frees up available bed days, and may be cost neutral or cost saving depending on the assumed LOS, compared to vancomycin.

Conference/Value in Health Info

2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands

Value in Health, Vol. 17, No. 7 (November 2014)

Code

PIN25

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Infectious Disease (non-vaccine)

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×